Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan

Abstract

Background

Painful paronychia and pseudopyogenic granuloma (PG) are common adverse drug reactions (ADRs) associated with the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) to treat non-small cell lung cancer (NSCLC). Multiple local management approaches have been tested with unsatisfactory results. We have introduced an occlusion therapy technique through which available topical drugs for longer than 2 years.

Methods

Based on the cancer registry and case management system of our hospital, from July 2019 to July 2020, we retrospectively enrolled patients with NSCLC who were treated with EGFR-TKIs and received applications of 0.5% timolol ophthalmic solution (TIMOPTOL XE 0.5%®) combined with a neomycin/tyrothricin ointment (Biomycin®) using the occlusion method to treat paronychia or PG.

Results

A total of 22 patients were enrolled, with a mean age of 66.5 years, most of whom were women (72.7%). Periungual lesion-related pain was reported by all patients, and periungual bleeding and PG were reported in 14% (3/22) and 64% (14/22) of patients, respectively. After the occlusion therapy application of timolol ophthalmic solution combined with neomycin/tyrothricin ointment twice daily, the overall response rate was 83.3%, including complete response in 18% (4/22) of cases and partial response in 68% (15/22) of cases.

Conclusion

We presented an occlusion method using available topical beta-blockers and antibiotic ointment for EGFR-TKI-induced paronychia and PG in Taiwan. The result is favorable. Further randomized control trial is urgent to validate our findings

Keywords

Beta-blockers epidermal growth factor receptor tyrosine kinase inhibitor paronychia pyogenic granulomas

Get full access to this article

View all access options for this article.

References

da Cunha Santos

Shepherd

Tsao

. EGFR mutations and lung cancer. Annu Rev Pathol 2011; 6: 49–69.

Lacouture

. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803–812.

Hsu

Yang

Mok

, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol 2018; 29:i3–i9.

Leggit

. Acute and chronic paronychia. Am Fam Physician 2017; 96: 44–51. https://www.ncbi.nlm.nih.gov/pubmed/28671378

Ramesh

. Pyogenic granuloma-like lesions due to antifungal-corticosteroid combination creams. Indian J Dermatol Venereol Leprol 2021; 87: 854–855.

Kozuki

. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol 2016; 46: 291–298.

Mok

Thongprasert

, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–957.

Zhou

Chen

, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–742.

Yang

Schuler

, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141–151.

10.

Califano

Tariq

Compton

, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs 2015; 75: 1335–1348.

11.

Chen

Tsai

Lee

, et al. Lower starting dose of Afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. BMC cancer 2021; 21: 95.

12.

Yang

Tsai

Hung

, et al. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung adenocarcinoma harboring exon 19 or exon 21 mutations. BMC Pharmacol Toxicol 2017; 18: 82.

13.

Sibaud

Casassa

D'Andrea

. Are topical beta-blockers really effective “in real life” for targeted therapy-induced paronychia. Support Care Cancer 2019; 27: 2341–2343.

14.

Chisholm

Chang

Truong

, et al. Beta-adrenergic receptor expression in vascular tumors. Mod Pathol 2012; 25: 1446–1451.

15.

Kaur

Tchanque-Fossuo

West

, et al. Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study. Trials 2020; 21: 496.

16.

Pullar

Rizzo

Isseroff

. Beta-adrenergic receptor antagonists accelerate skin wound healing: evidence for a catecholamine synthesis network in the epidermis. J Biol Chem 2006; 281: 21225–21235.

17.

Sollena

Mannino

Tassone

, et al. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. Drugs Context 2019; 8: 212613.

18.

Melosky

Hirsh

. Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIs. Front Oncol 2014; 4: 38.

19.

Lin

Yang

, et al. Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life. J Eur Acad Dermatol Venereol 2019; 33: 204–212.

20.

Sano

Itami

Takeda

, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999; 18: 4657–4668.

21.

Melosky

Leighl

Rothenstein

, et al. Management of egfr tki-induced dermatologic adverse events. Curr Oncol 2015; 22: 123–132.

22.

Goodarzi

Mozafarpoor

Dodangeh

, et al. The role of topical timolol in wound healing and the treatment of vascular lesions: a narrative review. Dermatol Ther 2021; 34: e14847.

23.

Filoni

Ambrogio

De Marco

, et al. Topical beta-blockers in dermatologic therapy. Dermatol Ther 2021; 34: e15016.

24.

Olamiju

Bhullar

Coleman

, et al. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: an assessment of topical timolol and the need for multiple medical and procedural therapies. J Am Acad Dermatol 2021; 84: 806–808.

25.

Yen

Hsu

Yang

, et al. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. Int J Dermatol 2020; 59: 326–332.

26.

Wang

Yen

, et al. Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: a case-control cohort study. Int J Dermatol 2021; 60: 179–184.

27.

Piraccini

Alessandrini

Dika

, et al. Topical propranolol 1% cream for pyogenic granulomas of the nail: open-label study in 10 patients. J Eur Acad Dermatol Venereol 2016; 30: 901–902.

28.

MSY

Tay

, et al. Comparison of two formulations of topical timolol for the treatment of infantile hemangiomas. Pediatr Dermatol 2017; 34: 492–493.

29.

Jeon

Cohen

. Lack of efficacy of topical timolol for cutaneous telangiectasias in patients with hereditary hemorrhagic telangiectasia: results of a pilot study. J Am Acad Dermatol 2017; 76: 997–999.